# Trial of Ulixertinib in Combination With Hydroxychloroquine in Patients With Advanced Gastrointestinal (GI) Malignancies

> **NCT05221320** · PHASE2 · TERMINATED · sponsor: **BioMed Valley Discoveries, Inc** · enrollment: 47 (actual)

## Conditions studied

- Tumor, Solid
- Gastrointestinal Cancer

## Interventions

- **DRUG:** Ulixertinib
- **DRUG:** Hydroxychloroquine

## Key facts

- **NCT ID:** NCT05221320
- **Lead sponsor:** BioMed Valley Discoveries, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-05-26
- **Primary completion:** 2024-05-08
- **Final completion:** 2024-07-14
- **Target enrollment:** 47 (ACTUAL)
- **Why stopped:** Lack of Enrollment for Remaining Open Baskets
- **Last updated:** 2025-09-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05221320

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05221320, "Trial of Ulixertinib in Combination With Hydroxychloroquine in Patients With Advanced Gastrointestinal (GI) Malignancies". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT05221320. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*